Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Bivalent and 9-Valent HPV Vaccine Immunization in Girls Aged 9-14 Years
NCT07281677Phase 4Active, not recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of Human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine, recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection. Started Dec 2025; status: active, not recruiting.
02
Drugs
Human papillomavirus 16/18 L1 virus-like particle/AS04 vaccinerecombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT07281677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281677.